PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30128710-0 2018 Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. Aspirin 0-7 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 116-123 31171523-13 2019 CONCLUSION: Patients with minor stroke or transient ischaemic attack who are treated with ticagrelor plus aspirin have a lower proportion of high platelet reactivity than those who are treated with clopidogrel plus aspirin, particularly for those who are carriers of the CYP2C19 loss-of-function allele. Aspirin 106-113 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 271-278 30772975-3 2019 Loss-of-function allele carriers of CYP2C19 were included and randomly divided into loading dose group (first dose of 300 mg clopidogrel) and standard dose group (first dose of 75 mg clopidogrel), 100 mg aspirin was gave at the same time, followed by aspirin 100 mg/d plus clopidogrel 75 mg/d maintaining for 20 days. Aspirin 204-211 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 36-43 30772975-3 2019 Loss-of-function allele carriers of CYP2C19 were included and randomly divided into loading dose group (first dose of 300 mg clopidogrel) and standard dose group (first dose of 75 mg clopidogrel), 100 mg aspirin was gave at the same time, followed by aspirin 100 mg/d plus clopidogrel 75 mg/d maintaining for 20 days. Aspirin 251-258 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 36-43 29520080-13 2018 Among patients with minor stroke or TIA taking clopidogrel-aspirin treatment, CYP2C19 LOF carrier state was associated with higher risk of new stroke in those with eGFR < 75 ml/min/1.73 m2. Aspirin 59-66 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 78-85 30061570-1 2019 The effect of dual antiplatelet therapy, clopidogrel combined with aspirin, was influenced by CYP2C19 gene mutation and heterogeneity of population. Aspirin 67-74 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 94-101 30128710-11 2018 Stratified analyses revealed that clopidogrel plus aspirin could be more effective in reducing END than aspirin alone for carriers of CYP2C19*2 reduced-function alleles (18.8 vs. 34.9%, P = 0.006). Aspirin 51-58 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 134-141 30128710-13 2018 CONCLUSIONS: Dual therapy with clopidogrel and aspirin may be adequate for prevention of END in carriers of CYP2C19 reduced-function alleles, but not for noncarriers. Aspirin 47-54 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 108-115 29804161-0 2018 Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. Aspirin 34-41 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 121-128 29804161-13 2018 Dual therapy with clopidogrel and aspirin may be adequate for patients carrying CYP2C19*2 reduced-function alleles. Aspirin 34-41 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 80-87 29936693-0 2018 Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel. Aspirin 193-200 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 24-31 29936693-2 2018 The aim of this pilot prospective study was to evaluate 12-month cardiovascular outcomes in elderly patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy (aspirin and clopidogrel) according to the clustering of CYP2C19 and ABCB1 genetic variants. Aspirin 181-188 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 237-244 29743380-1 2018 BACKGROUND: Patients with reduced-function CYP2C19 genotypes on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel show higher clinical risk for acute myocardial infarction (AMI). Aspirin 102-109 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 43-50 29901608-0 2018 Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis. Aspirin 145-152 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 23-30 29901608-1 2018 BACKGROUND: The relationship of CYP2C19 genotype and clinical efficacy in stroke or transient ischemic attack (TIA) patients treated with clopidogrel monotherapy or clopidogrel plus aspirin remains unknown. Aspirin 182-189 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 32-39 28381198-2 2017 This study aimed to evaluate whether the combination of ticagrelor and aspirin was superior to that of clopidogrel and aspirin in reducing the 90-day high on-treatment platelet reactivity for acute minor stroke or transient ischemic attack, especially for carriers of cytochrome P450 2C19 loss-of-function allele. Aspirin 71-78 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 268-288 29407631-9 2018 CONCLUSIONS: For Chinese patients with ACS treated with aspirin and clopidogrel, genetic mutations in rs822441/rs822442 in PEAR1 correlated significantly with platelet activity after adjusting for CYP2C19 *2/*3 alleles. Aspirin 56-63 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 197-204 26773298-8 2016 In the aspirin/clopidogrel group, the PL24 -AUC10 was higher in poor metabolizers (PMs) with cytochrome P450 2C19(CYP2C19) polymorphisms (152 +- 112, 95% CI 103.4-200.6) than in the non-PM group (87 +- 74, 95% CI 73.8-100.2). Aspirin 7-14 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 93-113 28289237-8 2017 CONCLUSIONS: In patients with minor stroke or high-risk transient ischemic attack, clopidogrel-aspirin when compared with aspirin alone reduced stroke recurrence only in noncarriers of CYP2C19 loss-of-function allele and normal GA levels. Aspirin 95-102 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 185-192 27348249-13 2016 CONCLUSIONS AND RELEVANCE: Among patients with minor ischemic stroke or transient ischemic attack, the use of clopidogrel plus aspirin compared with aspirin alone reduced the risk of a new stroke only in the subgroup of patients who were not carriers of the CYP2C19 loss-of-function alleles. Aspirin 127-134 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 258-265 26773298-8 2016 In the aspirin/clopidogrel group, the PL24 -AUC10 was higher in poor metabolizers (PMs) with cytochrome P450 2C19(CYP2C19) polymorphisms (152 +- 112, 95% CI 103.4-200.6) than in the non-PM group (87 +- 74, 95% CI 73.8-100.2). Aspirin 7-14 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 114-121 26019129-7 2015 CONCLUSIONS: There were significant differences in recurrent stroke by CYP2C19 genotype-inferred metabolizer status in white subcortical stroke patients receiving dual antiplatelet therapy with aspirin and clopidogrel, consistent with cardiovascular studies on CYP2C19 and clopidogrel; however, the bleeding risk that led to early termination of the antiplatelet arm of the SPS3 trial does not appear to be explained by CYP2C19 genotype. Aspirin 194-201 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 71-78 26264906-0 2015 Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease. Aspirin 70-77 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 15-22 26828987-8 2016 Additionally, it was found that patients who have clopidogrel and/or aspirin resistance also have CYP2C19*1/*2 or CYPC19*2/*2 genotype. Aspirin 69-76 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 98-105 19429918-0 2009 Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Aspirin 124-131 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 21-28 24418943-3 2014 To evaluate an impact of CYP2C19 G681A and CYP4F2 G1347A polymorphisms and clinical factors on dual antiplatelet effect of clopidogrel and aspirin. Aspirin 139-146 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 25-32 24088578-1 2014 AIM: Carriers of the reduced-function CYP2C19 allele receiving dual antiplatelet therapy (DAPT) with aspirin and clopidogrel exhibit diminished platelet inhibition and an increased risk of events. Aspirin 101-108 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 38-45 22542748-0 2012 Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype. Aspirin 91-98 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 110-117 21855977-0 2011 Polymorphisms of the CYP2C19 gene in Japanese patients with aspirin-exacerbated respiratory disease. Aspirin 60-67 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 21-28 20848331-9 2009 Certain polymorphisms (eg, CYP2C19) may prevent this conversion and lead to failure of clopidogrel to prevent major cardiovascular events.In patients with well-controlled or treated cardiovascular risk factors, aspirin plus extended-release dipyridamole and clopidogrel may provide similar results in preventing recurrent stroke, but aspirin plus extended-release dipyridamole may be associated with a slightly higher risk of major hemorrhage. Aspirin 211-218 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 27-34 20848331-9 2009 Certain polymorphisms (eg, CYP2C19) may prevent this conversion and lead to failure of clopidogrel to prevent major cardiovascular events.In patients with well-controlled or treated cardiovascular risk factors, aspirin plus extended-release dipyridamole and clopidogrel may provide similar results in preventing recurrent stroke, but aspirin plus extended-release dipyridamole may be associated with a slightly higher risk of major hemorrhage. Aspirin 334-341 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 27-34 12621391-6 2003 RESULTS: Both 7-day and 14-day aspirin intake increased the activity of CYP2C19 significantly, as indicated by 4-hydroxymephenytoin urinary recovery (P <.001). Aspirin 31-38 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 72-79 12621391-11 2003 Both 7-day and 14-day low-dose aspirin induced the in vivo activities of CYP2C19 but did not affect the activities of CYP1A2, CYP2D6, and CYP2E1. Aspirin 31-38 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 73-80 12621391-13 2003 When low-dose aspirin is used in combination with drugs that are substrates of CYP2C19, doses of the latter should be adjusted to ensure their efficacy. Aspirin 14-21 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 79-86 12621391-7 2003 Induction of low-dose aspirin on CYP2C19 was time-dependent. Aspirin 22-29 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 33-40 34666508-11 2022 Our study suggests that CYP2C19 genotypes and clinical risk factors can be integrated by ABCD-GENE score to estimate the efficacy of clopidogrel-aspirin therapy. Aspirin 145-152 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 24-31 33795788-4 2021 In order to optimize antiplatelet therapy for these patients and avoid the waste of medical resources, it is important to identify the subgroups that genuinely benefit from DAPT with clopidogrel plus aspirin through CYP2C19 genotyping. Aspirin 200-207 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 216-223 34851561-3 2021 The aim was to investigate the association between presence of the CYP2C19*2 allele and ISR within one-year after PCI in patients prescribed dual antiplatelet therapy with aspirin and clopidogrel. Aspirin 172-179 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 67-74 32568642-2 2020 The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) found a significant interaction between loss-of-function allele status for the CYP2C19 gene and the effect of dual antiplatelet therapy with aspirin and clopidogrel on the rate of early recurrent stroke following acute transient ischemic attack/minor stroke. Aspirin 241-248 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 179-186 34471538-3 2021 Studies reported the genetic polymorphisms of CYP2C19*2, CYP2C19*17, and ITGB3 cause an alteration of the pharmacodynamic and pharmacokinetic profile of aspirin and clopidogrel. Aspirin 153-160 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 46-53 34471538-3 2021 Studies reported the genetic polymorphisms of CYP2C19*2, CYP2C19*17, and ITGB3 cause an alteration of the pharmacodynamic and pharmacokinetic profile of aspirin and clopidogrel. Aspirin 153-160 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 57-64 33411687-7 2020 IPA was higher at all time points except at baseline in patients with ticagrelor/aspirin compared with those with clopidogrel/aspirin in both carriers and non-carriers of CYP2C19 lose-of-function alleles (all p<0.05). Aspirin 126-133 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 171-178 33121452-0 2020 Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial. Aspirin 55-62 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 107-114 33121452-11 2020 CONCLUSIONS: In patients with ischaemic stroke who had a single CYP2C19 loss-of-function allele and moderate to severe cerebral stenosis, fewer vascular events occurred within 3 months with high dose of clopidogrel and aspirin than with normal dose of clopidogrel and aspirin. Aspirin 219-226 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 64-71 33121452-11 2020 CONCLUSIONS: In patients with ischaemic stroke who had a single CYP2C19 loss-of-function allele and moderate to severe cerebral stenosis, fewer vascular events occurred within 3 months with high dose of clopidogrel and aspirin than with normal dose of clopidogrel and aspirin. Aspirin 268-275 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 64-71 35000048-0 2022 COX-1, COX-2 and CYP2C19 variations may be related to cardiovascular events due to acetylsalicylic acid resistance. Aspirin 83-103 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 17-24 33455983-5 2021 Genetic testing found that both cytochrome P450 2C19 (CYP2C19) (G681A) and glycoprotein Ia (GPIa) (C807T, G873A) were hybrid mutant types, demonstrating that the patient was possibly resistant to clopidogrel and aspirin simultaneously. Aspirin 212-219 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 32-52 33455983-5 2021 Genetic testing found that both cytochrome P450 2C19 (CYP2C19) (G681A) and glycoprotein Ia (GPIa) (C807T, G873A) were hybrid mutant types, demonstrating that the patient was possibly resistant to clopidogrel and aspirin simultaneously. Aspirin 212-219 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 54-61 32376540-7 2020 CONCLUSIONS: For stable angina patients with complicated left main coronary artery lesions and intermediate metabolizer CYP2C19 gene, aspirin combined with ticagrelor antiplatelet therapy after PCI is effective, the effect of ticagrelor is better than clopidogrel on MACE, and ticagrelor does not seem to increase the risk of bleeding. Aspirin 134-141 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 120-127 31131755-0 2020 Association of CYP2C19 and HSP70 genes polymorphism with aspirin-exacerbated respiratory disease in Kurdistan province. Aspirin 57-64 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 15-22 31131755-2 2020 Recently, polymorphism in CYP2C19 and HSP genes has been observed in aspirin-exacerbated respiratory disease (AERD). Aspirin 69-76 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 26-33 31726963-9 2020 Our study suggests that BMI significantly influences the correlation between CYP2C19 genotype and efficacy of clopidogrel-aspirin therapy. Aspirin 122-129 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 77-84 30974489-10 2019 Amongst smokers, clopidogrel plus aspirin might decrease the recurrence rate of stroke in non-carriers of *2 and *3 alleles of CYP2C19 compared with aspirin alone. Aspirin 34-41 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 127-134